Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Biomarkers for Ventilator-associated Pneumonia

Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Who May Be Eligible (Plain English)

Who May Qualify: - Admission to an intensive care unit - Intubation within last 24 hours - Anticipated mechanical ventilation of at least 48 hours Who Should NOT Join This Trial: - FiO2 above 70% or PEEP above 15 - Severe coagulopathy (spontaneous PK(INR) \>1.8 or thrombocytes \<50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors/NOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection. - Ongoing infection of the lungs at admission to the ICU. - Severely elevated or instable intracranial pressure. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Admission to an intensive care unit * Intubation within last 24 hours * Anticipated mechanical ventilation of at least 48 hours Exclusion Criteria: * FiO2 above 70% or PEEP above 15 * Severe coagulopathy (spontaneous PK(INR) \>1.8 or thrombocytes \<50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors/NOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection. * Ongoing infection of the lungs at admission to the ICU. * Severely elevated or instable intracranial pressure.

Treatments Being Tested

DIAGNOSTIC_TEST

Heparin-binding protein

Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.

DIAGNOSTIC_TEST

Interleukin-26

Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

DIAGNOSTIC_TEST

Microbiome

Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

DIAGNOSTIC_TEST

Bacterial transcriptome

Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.

DIAGNOSTIC_TEST

Proteome

Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Locations (5)

Vestre Viken
Drammen, Norway
Hospital de São Francisco Xavier
Lisbon, Portugal
Skåne University Hospital, Dept. of Infectious diseases
Lund, Sweden
Skåne university Hospital, ICU
Malmo, Sweden
Karolinska University Hospital, ICU
Solna, Sweden